



**BAYER**

**4D Pharma**

Pipeline • Products • Performance • Potential

# CONTENTS

Latest Results .....	2
<b>EXECUTIVE SUMMARY .....</b>	<b>5</b>
Introduction .....	5
Financial Performance 2008 .....	6
Business Segment Performance .....	10
Geographical Segment Breakdown .....	14
Company Strategy .....	18
Research and Development Strategy .....	19
Key Agreements .....	20
Discontinued Agreements .....	21
Mergers, Acquisitions and Divestitures .....	22
Manufacturing .....	24
Employees .....	24
Product Performance Forecasts .....	26
Pipeline Analysis .....	29
Discontinued Projects .....	30
Other Factors Affecting The Bottom Line .....	31
Conclusions/Outlook .....	33
<b>THERAPEUTIC AREA FOCUS.....</b>	<b>37</b>
<b>R&amp;D PIPELINE .....</b>	<b>39</b>
<b>PRIMARY CARE .....</b>	<b>41</b>
Marketed Products .....	41
Adalat .....	41
Avelox/Avalox .....	43
Cipro/Ciprobay .....	47
Glucobay .....	52
Kinzalmono .....	54
Levitra/Vivanza .....	55
Others .....	58
R&D Projects .....	60
eF-Ment .....	60
Lipoxin .....	60
NKTR-061 .....	60
Growth Forecast .....	62
<b>WOMEN'S HEALTHCARE .....</b>	<b>63</b>
Marketed Products .....	63
Angeliq .....	63
Mirena .....	64
Yasmin .....	65
Others .....	68
R&D Projects .....	71
E2/LNG pill .....	71
E2/DRSP .....	71
E2/DHEA .....	71
LCS .....	71
Visanne .....	72
Growth Forecast .....	73
<b>DIAGNOSTIC IMAGING.....</b>	<b>75</b>
Marketed Products .....	75

Magnevist .....	75
Vasovist .....	76
Others .....	78
<b>R&amp;D Projects .....</b>	<b>80</b>
BAY 94-9172 (AV1/ZK) .....	80
Growth Forecast .....	81
<b>SPECIALIZED THERAPEUTICS .....</b>	<b>82</b>
Marketed Products .....	82
Betaferon/Betaseron .....	82
Sativex .....	86
Other CNS Products .....	91
R&D Projects .....	92
VEGF Trap-Eye .....	92
Growth Forecast .....	94
<b>HAEMATOLOGY / CARDIOLOGY .....</b>	<b>97</b>
Marketed Products .....	97
Kogenate/Kogenate FS .....	97
Recothrom .....	101
Trasylol .....	101
Xarelto .....	104
Others .....	107
R&D Projects .....	108
Cinaciguat .....	108
Riociguat .....	108
BAY 68-4986 .....	110
BAY 71-9678 .....	110
Growth Forecast .....	111
<b>ONCOLOGY .....</b>	<b>113</b>
Marketed Products .....	113
Nexavar .....	113
Zevalin .....	118
Others .....	120
R&D Projects .....	122
Alpharadin .....	122
BAY 73-4506 .....	124
L19 .....	125
Lonaprisan .....	125
Sagopilone .....	125
Growth Forecast .....	127
<b>APPENDIX 1 - FINANCIAL PERFORMANCE .....</b>	<b>131</b>
Full Year Results 2008 .....	131
<b>APPENDIX 2 - KEY AGREEMENTS.....</b>	<b>134</b>
Abbott .....	134
Actimis Pharmaceuticals .....	134
Activaero Technologies GmbH .....	134
Algeta ASA .....	134
Amerinet Inc .....	135
Ardea Biosciences Inc .....	135
Asklepios Biopharmaceutical Inc .....	136
Astex Technology .....	136
AstraZeneca .....	136

Avid Radiopharmaceuticals Inc.....	137	Taisho Pharmaceutical.....	161
Barr Laboratories Inc.....	138	Titan Pharmaceuticals.....	162
Biogen Idec/Cell Therapeutics Inc.....	138	Vaccinex Inc.....	162
Bioton SA.....	139	Warner Chilcott.....	162
Boehringer Ingelheim.....	139	Xanthus Pharmaceuticals Inc.....	163
Celera Genomics.....	139	Zilip-Pharma.....	163
Cell Therapeutics Inc.....	139	ZymoGenetics Inc.....	164
ChemDiv Inc.....	140	<b>APPENDIX 3 - INFRASTRUCTURE..... 165</b>	
CoTherix Inc.....	140	<b>Research and Development Facilities..... 165</b>	
CSL Behring.....	140	<b>Manufacturing Facilities..... 166</b>	
CuraGen Corporation.....	140	<b>APPENDIX 4 - KEY PHARMACEUTICAL</b>	
Cytogen Corporation.....	142	<b>SUBSIDIARIES / JOINT VENTURES..... 167</b>	
Daiichi Sankyo.....	142	<b>Subsidiaries..... 167</b>	
DARA Biosciences Inc.....	142	<b>Joint-venture Companies..... 168</b>	
deCODE genetics.....	143	<b>APPENDIX 5 - PRODUCT INDEX..... 169</b>	
Dyax Corporation.....	143		
E-Z-EM Inc.....	143		
EPIX Pharmaceuticals.....	144		
First Horizon Pharmaceutical Corporation.....	144		
Faville Inc.....	145		
Fresenius Kabi AG.....	145		
Genstruct Inc.....	145		
Genzyme Corporation.....	146		
GlaxoSmithKline.....	148		
GW Pharmaceuticals plc.....	149		
Indevus Pharmaceuticals Inc.....	149		
ImmunoGen Inc.....	150		
Johnson & Johnson.....	150		
Mallinckrodt Inc.....	150		
Memory Pharmaceuticals Inc.....	151		
Micromet Inc.....	151		
Millennium Pharmaceuticals Inc.....	151		
Mitsubishi Tanabe Pharma.....	152		
Monash University.....	153		
Morphosys AG.....	153		
Nektar Therapeutics Corporation.....	153		
Novartis.....	154		
OncoGeneX Pharmaceuticals Inc.....	155		
Onyx Pharmaceuticals Inc.....	156		
Peregrine Pharmaceuticals Inc.....	157		
Pfizer.....	157		
Philogen Srl.....	157		
ProStrakan Group Plc.....	158		
Ranbaxy Laboratories Limited.....	158		
Regeneron Pharmaceuticals Inc.....	158		
sanofi-aventis.....	159		
Schering-Plough.....	160		
Shionogi.....	160		
Siemens Medical Solutions.....	160		
Stanford University.....	161		
Syndax Pharmaceuticals Inc.....	161		

## INDEX OF TABLES

<i>Principal Operating Results</i> .....	1
<i>Capital Expenditure By Business Area</i> .....	7
<i>Capital Expenditure By Geographic Area</i> .....	8
<i>Research And Development Expenditure By Business Area</i> .....	9
<i>Research And Development By Geographic Area</i> .....	10
<i>Sales By Business Area</i> .....	12
<i>Operating Income (Loss) By Business Area</i> .....	13
<i>Sales By Destination</i> .....	15
<i>Sales By Origin</i> .....	16
<i>Operating Income (Loss) By Geographical Area</i> .....	17
<i>Recent Product Approvals</i> .....	28
<i>Major Products, Therapeutic Areas And Sales</i> .....	37
<i>Major Primary Care Products, 2008</i> .....	41
<i>Major Women's Health Products, 2008</i> .....	63
<i>Major Diagnostic Imaging Products, 2008</i> .....	75
<i>Major Specialized Therapeutics Products, 2008</i> .....	82
<i>Major Haematology/Cardiology Products, 2008</i> .....	97
<i>Major Oncology Products, 2008</i> .....	113

## INDEX OF CHARTS

<i>Sales, Costs and Operating Income</i> .....	6
<i>Capital Expenditure By Business Area, 2008</i> .....	7
<i>Capital Expenditure By Geographic Area, 2008</i> .....	8
<i>Research and Development Expenditure By Business Area, 2008</i> .....	9
<i>Research and Development By Geographic Area, 2008</i> .....	10
<i>Sales By Business Area, 2008</i> .....	12
<i>Operating Income By Business Area</i> .....	13
<i>Sales By Destination</i> .....	15
<i>Sales By Origin</i> .....	16
<i>Operating Income By Geographical Area</i> .....	17
<i>Sales of Current Major Products (2003A-2013E)</i> .....	27
<i>Sales By Major Product, 2008</i> .....	38
<i>Adalat Sales (2003A-2013E)</i> .....	43
<i>Avalox/Avelox Sales (2003A-2013E)</i> .....	46
<i>Cipro/Ciprobay Sales (2003A-2013E)</i> .....	52
<i>Glucobay Sales (2003A-2013E)</i> .....	54
<i>Levitra Sales (2003A-2013E)</i> .....	57
<i>Mirena Sales (2003A-2013E)</i> .....	65
<i>Yasmin/YAZ sales (2003A-2013E)</i> .....	68
<i>Magnevist sales (2003A-2013E)</i> .....	76
<i>Betaferon/Betaseron sales (2003A-2013E)</i> .....	85
<i>Kogenate Sales (2003A-2013E)</i> .....	100
<i>Rivaroxaban Sales (2009E-2015E)</i> .....	105
<i>Nexavar sales (2006A-2013E)</i> .....	117
<i>Sales, Costs and Operating Income</i> .....	132
<i>Profitability and Research Ratios</i> .....	132
<i>R&amp;D Expenditure and Capital Expenditure</i> .....	132
<i>Current Assets, Liabilities and Ratio</i> .....	133
<i>Assets, Cash and Liquidity</i> .....	133
<i>Employees and Productivity</i> .....	133